RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T20:53:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -164.92200M | -123.82000M | -195.96400M | -199.55000M | -178.38100M |
| Minority interest | - | - | - | - | - |
| Net income | -165.29100M | -124.08800M | -196.27300M | -199.59000M | -178.40700M |
| Selling general administrative | 145.40M | 143.85M | 126.42M | 105.42M | 48.85M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 151.86M | 206.42M | 105.38M | 38.49M | 30.34M |
| Reconciled depreciation | 0.62M | 0.79M | 0.97M | 0.97M | 0.73M |
| Ebit | -142.20200M | -98.27100M | -171.85000M | -189.27500M | -179.88300M |
| Ebitda | -139.92600M | -97.77400M | -168.82400M | -183.90300M | -175.88800M |
| Depreciation and amortization | 2.28M | 0.50M | 3.03M | 5.37M | 4.00M |
| Non operating income net other | 2.28M | 0.50M | 3.03M | 5.37M | 4.00M |
| Operating income | -142.20200M | -98.27100M | -171.85000M | -189.27500M | -179.88300M |
| Other operating expenses | 299.28M | 308.09M | 279.94M | 230.17M | 210.22M |
| Interest expense | 25.00M | 26.05M | 27.14M | 15.65M | 2.49M |
| Tax provision | 0.37M | 0.27M | 0.31M | 0.04M | 0.03M |
| Interest income | 2.36M | 0.58M | 2.82M | 5.42M | 4.03M |
| Net interest income | -22.63700M | -25.46400M | -24.32000M | -10.22500M | 1.53M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.37M | 0.27M | 0.31M | 0.04M | 0.03M |
| Total revenue | 157.07M | 209.82M | 108.08M | 40.89M | 30.34M |
| Total operating expenses | 294.06M | 304.69M | 277.23M | 227.76M | 210.22M |
| Cost of revenue | 5.21M | 3.40M | 2.71M | 2.41M | 161.37M |
| Total other income expense net | -22.72000M | -25.54900M | -24.11400M | -10.27500M | 1.50M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -165.29100M | -124.08800M | -196.27300M | -199.59000M | -178.40700M |
| Net income applicable to common shares | -165.29100M | -124.08800M | -196.27300M | -199.59000M | -178.40700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 240.44M | 358.17M | 305.31M | 313.05M | 294.96M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 11.81M | 19.82M | 2.88M | 0.56M | 1.49M |
| Total liab | 376.64M | 374.83M | 384.98M | 262.50M | 245.19M |
| Total stockholder equity | -136.20600M | -16.65600M | -79.67300M | 50.55M | 49.77M |
| Deferred long term liab | - | - | - | - | 2.19M |
| Other current liab | 63.05M | 60.26M | 0.68M | -6.36700M | 41.38M |
| Common stock | 0.01M | 0.01M | 0.00800M | 0.00700M | 0.00700M |
| Capital stock | 0.01M | 0.01M | 0.00800M | 0.00700M | 0.00700M |
| Retained earnings | -1487.03800M | -1343.93900M | -1178.64800M | -1069.61100M | -873.33800M |
| Other liab | - | - | 215.69M | 144.58M | 75.78M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.63M | 45.56M | 34.30M | 0.71M |
| Cash | 52.89M | 135.19M | 190.46M | 85.92M | 128.86M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 69.48M | 65.91M | 73.72M | 0.30M | 46.35M |
| Current deferred revenue | - | - | 69.12M | 0.30M | 2.34M |
| Net debt | 124.12M | 37.79M | -21.16600M | 32.01M | -19.00100M |
| Short term debt | 3.31M | 2.87M | 2.32M | 1.92M | 1.65M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 177.02M | 172.98M | 169.29M | 117.93M | 109.86M |
| Other stockholder equity | 1350.98M | 1327.91M | 1098.78M | 1119.63M | 923.14M |
| Property plant equipment | - | 1.14M | 1.64M | 2.22M | 3.05M |
| Total current assets | 233.92M | 326.75M | 258.10M | 289.54M | 273.67M |
| Long term investments | - | - | 0.00000M | 24.21M | 2.02M |
| Net tangible assets | - | -16.65600M | -79.67300M | 50.55M | 49.77M |
| Short term investments | 139.21M | 142.78M | 38.16M | 163.32M | 133.10M |
| Net receivables | 26.96M | 47.09M | 22.50M | 12.88M | 7.86M |
| Long term debt | 170.92M | 170.10M | 169.29M | 117.93M | 109.86M |
| Inventory | 3.04M | 4.22M | 4.11M | 2.64M | 0.35M |
| Accounts payable | 3.12M | 2.77M | 1.60M | 4.45M | 0.98M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.16100M | -0.63800M | 0.19M | 0.52M | -0.03700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.01M | 0.00800M | 0.00700M | 0.00700M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1343.93900M | -1178.64800M | -1069.61100M | -873.33800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.33M | 24.05M | 45.56M | -2.92300M | 16.24M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6.52M | 31.42M | 47.21M | 23.51M | 21.30M |
| Capital lease obligations | 6.10M | 8.97M | 11.29M | 13.20M | 14.85M |
| Long term debt total | - | - | - | 117.93M | 109.86M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -104.13800M | 147.55M | -53.54000M | 78.66M | -105.30100M |
| Change to liabilities | -8.36600M | 13.41M | 15.63M | 5.21M | 9.88M |
| Total cashflows from investing activities | -104.25600M | 141.84M | -53.68500M | 78.45M | -107.66400M |
| Net borrowings | - | - | - | - | 166.88M |
| Total cash from financing activities | 193.74M | 73.65M | 172.08M | 124.31M | 316.11M |
| Change to operating activities | -15.95700M | -8.96700M | 9.77M | 7.56M | 9.24M |
| Net income | -165.29100M | -124.08800M | -196.27300M | -199.59000M | -178.40700M |
| Change in cash | -60.56000M | 108.32M | -41.56800M | 11.95M | 49.25M |
| Begin period cash flow | 197.44M | 89.12M | 130.69M | 118.74M | 69.49M |
| End period cash flow | 136.88M | 197.44M | 89.12M | 130.69M | 118.74M |
| Total cash from operating activities | -149.55400M | -107.11600M | -160.23400M | -190.82200M | -159.11700M |
| Issuance of capital stock | 189.76M | 9.90M | 161.78M | 46.19M | 145.71M |
| Depreciation | 0.62M | 0.79M | 0.97M | 0.97M | 0.73M |
| Other cashflows from investing activities | - | -5.50000M | - | 78.66M | -105.30100M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.11800M | -1.46200M | -2.62700M | -0.34600M | -0.34600M |
| Change to account receivables | -5.08400M | -9.61600M | -5.01900M | -7.86200M | -7.86200M |
| Sale purchase of stock | 3.98M | 3.75M | 10.31M | 4.50M | 3.52M |
| Other cashflows from financing activities | 3.98M | 63.74M | 10.31M | 78.11M | 170.40M |
| Change to netincome | 35.12M | 37.03M | 24.22M | 15.29M | 17.27M |
| Capital expenditures | 0.12M | 5.71M | 0.14M | 0.21M | 2.36M |
| Change receivables | -5.08400M | -9.61600M | -5.01900M | -7.86200M | - |
| Cash flows other operating | -6.42100M | -25.52400M | -6.62400M | -10.31100M | -10.04400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -60.07200M | 108.37M | -41.83600M | 11.93M | 49.33M |
| Change in working capital | -19.98900M | -23.18900M | 1.36M | -13.30800M | -0.16900M |
| Stock based compensation | 35.40M | 29.78M | 24.41M | 15.29M | 17.27M |
| Other non cash items | -0.29400M | 8.13M | 8.40M | 7.19M | 1.42M |
| Free cash flow | -149.67200M | -112.82800M | -160.37900M | -191.02800M | -161.48000M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics Inc |
-0.0061 0.79% | 0.77 | - | - | 0.96 | 12.05 | 0.86 | -1.0617 |
| NVO Novo Nordisk A/S |
2.89 2.82% | 105.52 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.44 2.38% | 105.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.44 0.10% | 448.45 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-1.25 0.17% | 743.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
85 Wells Avenue, Newton, MA, United States, 02459-3298
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Paulson M.B.A. | Pres, CEO & Director | 1967 |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1970 |
| Mr. Michael P. Mason CPA, M.B.A. | Exec. VP, CFO & Treasurer | 1975 |
| Mr. Ran Frenkel R.Ph., RPh | Global Head of Clinical Operations | 1969 |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director | 1961 |
| Mr. Cameron Peters | VP of Fin., Assistant Treasurer & Principal Accounting Officer | 1960 |
| Mr. Pierre S. Sayad M.S., Ph.D. | VP of Global Medical & Scientific Affairs | NA |
| Ms. Elhan Webb C.F.A. | Sr. VP of Investor Relations | NA |
| Mr. Michael J. Mano J.D. | Sr. VP, Gen. Counsel & Sec. | 1977 |
| Mr. James Accumanno J.D. | Chief Compliance Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...